Potential of berberine to enhance antimicrobial activity of commonly used antibiotics for dairy cow mastitis caused by multiple drug-resistant *Staphylococcus epidermidis* infection

X. Zhou¹,², C. Yang¹,², Y. Li¹,², X. Liu¹,² and Y. Wang¹,²

¹Key Laboratory of Ministry of Education for Conservation and Utilization of Special Biological Resources in the Western China, Yinchuan, China
²College of Life Science, Ningxia University, Yinchuan, Ningxia, China
³Environment and Biotechnology Center, Faculty of Life and Social Sciences, Swinburne University of Technology, Victoria, Australia

Corresponding author: Y. Wang
E-mail: wyj@nxu.edu.cn

Received December 12, 2014
Accepted May 26, 2015
Published August 19, 2015
DOI http://dx.doi.org/10.4238/2015.August.19.1

**ABSTRACT.** Berberine is a plant alkaloid with antimicrobial activity against a variety of microorganisms. In this study, the antimicrobial properties of berberine against multi-drug resistant field isolates of *Staphylococcus epidermidis* were investigated using berberine alone or in combination with a commonly used antibiotics in veterinary clinics, including penicillin, lincomycin, and amoxicillin. The results indicated that the minimum inhibitory concentrations of berberine, penicillin, lincomycin, and amoxicillin against field *S. epidermidis* isolates were 2-512, 0.8-213, 0.4-1024, and 0.4-256 µg/mL, respectively. Furthermore, the synergestic effects of antimicrobial activity against these multi-drug resistant isolates were observed when the berberine was combined with penicillin, lincomycin, or amoxicillin; no antagonistic effect of the combination was detected in any of the clinical isolates.
These observations were further confirmed using a time-killing assay, in which a combination of 2 agents yielded a greater than 2.03-2.44 log$_{10}$ decrease in colony-forming unit/mL compared with each agent alone. These findings suggest that berberine is a promising compound for preventing and treating multi-drug resistant *S. epidermidis* infected mastitis in dairy cows either alone or in combination with other commonly used antibiotics, such as penicillin, lincomycin, and amoxicillin.

**Key words:** Antibiotics; Berberine; Dairy cow mastitis; *Staphylococcus epidermidis*

**INTRODUCTION**

*Staphylococcus epidermidis* is often considered to be a non-pathogenic bacterium, but it is a leading cause of hospital-acquired infections and is the most common pathogen associated with infections of surgical implants and other prosthetic devices in the hospital because of its adhesion properties and ability to form a biofilm on biomaterial surfaces (Gomes et al., 2012; Mekni et al., 2012). In veterinary practice, it is also one of the most prevalent species of coagulase-negative staphylococci (CNS) isolated from mastitis in dairy cows (Koop et al., 2012; Piessens et al., 2012). CNS is a group of the most frequently isolated microorganisms in cows and heifers in herds and the milk of goats and cows and is considered to be an emerging pathogen of bovine mastitis (Pyörälä and Taponen, 2009; Fernández-Rufete et al., 2012).

In animal clinical practice, variability in antimicrobial susceptibility to CNS, along with an increasing number of methicillin-resistant strains, has been observed, making it difficult to select an effective antibiotic for preventing and treating mastitis. Thus, individual susceptibility must be assessed to identify the optimal antibiotic treatment for mastitis (Zadoks et al., 2011). Previous studies using intramammary injection or systemic administration of penicillin, pirlimycin, or florfenicol have demonstrated a herd-level association between antimicrobial resistance and the use of antibiotics for *S. aureus* under field conditions (Saini et al., 2012). Recently, molecular epidemiological studies on mastitis pathogens and methicillin-resistant *S. aureus* (MRSA) in bovines and humans has revealed that the pathogens may not only share virulence factors, but also have distinct virulence factors that appear to be important in host adaptation. The exchange of genes encoding these virulence factors between strains may have a great impact on public health (Holmes and Zadoks, 2011; Zadoks et al., 2011). With the emergence of antibiotic-resistant bacterial isolates found in the mastitis of dairy livestock (Nickerson, 2009), as well as the increasing evidence of the *S. epidermidis*-related mastitis pathogen (Oliveira et al., 2006), identifying or developing a novel agent or regimen for preventing or treating of mastitis in dairy animals is necessary.

Berberine is a natural plant alkaloid present in the roots, rhizomes, and stem bark of many traditional herbal plants. It has important bioactivities, such as the maintenance of lipid and glucose levels, modulation of immunity and insulin sensitivity, and broad spectrum of antimicrobial activities against a variety of microorganisms, including bacteria and chlamydia. To date, the predominant medical uses of berberine include the control of intestinal infections, diabetes, and cholesterol (Derosa et al., 2012; Tillhon et al., 2012). Increasing evi-
dence suggests the potential antimicrobial properties of berberine against various bacterial pathogens, including MRSA and multi-drug resistant (MDR) \textit{S. epidermidis} isolates (Wang et al., 2009a;b; Xu et al., 2009), suggesting that it may be a promising agent for preventing and treating mastitis in animal practice when used alone or in combination with commonly used antibiotics. The objectives of this study were to explore the antimicrobial activity of berberine alone or in combination with commonly used antibiotics in veterinary practice, such as penicillin, lincomycin, or amoxicillin, against \textit{S. epidermidis} MDR field isolates from mastitis in dairy cows.

**MATERIAL AND METHODS**

**Bacterial strains**

Eighteen \textit{S. epidermidis} field isolates were isolated from the milk of dairy cows that were diagnosed with clinical mastitis, provided by the Center of Animal Disease Control and Prevention of the Ningxia Autonomous Region, China (Yinchuan, China) (Table 1 and 2). The reference strain of \textit{S. epidermidis} (FDA strain Seattle 1946, ATCC 12228) was obtained from the American Type Culture Collection (Manassas, VA, USA).

**Chemicals**

Chemicals used in this study were from Sigma (St. Louis, MO, USA), unless otherwise indicated. Muller-Hinton (MH) agar and MH broth were from Oxoid (Hampshire, UK). Lincomycin, amoxicillin, penicillin, and berberine were purchased from Pharmaceutical and Biological Products Inc. (Beijing, China). Lincomycin stock was freshly prepared as 1024 mg/mL solution in phosphate buffer (PB), pH 4.5; amoxicillin and penicillin were freshly prepared before use as stock solutions of 512 mg/mL in PB, pH 6.5; berberine stock was prepared as a solution with a concentration of 2048 μg/mL in PB, pH 5.5.

**In vitro determination of antibacterial susceptibility**

The methicillin resistance of the \textit{S. epidermidis} isolate was determined as an assay for MRSA following the NCCLS guideline using 30 μg cefoxitin and oxacillin. An isolate with an inhibition zone diameter of oxacillin inhibition ≤ 10 mm, or cefoxitin ≤19 mm was considered to be a methicillin-resistant isolate (NCCLS, 2004). The antibacterial activities against the above \textit{S. epidermidis} isolates were tested using an MH broth microdilution checkerboard method as previously described (Sun et al., 2009). Briefly, the bacterial culture was subcultured on MH agar and incubated at 37°C overnight. Single colonies were picked and inoculated into MH broth. The inoculum was adjusted to 1 x 10^6 colony-forming units (CFU)/mL by comparison with a 0.5X McFarland turbidity standard. Next, 100 μL bacterial suspension containing approximately 1 x 10^6 CFU was used to test susceptibility against berberine, penicillin, lincomycin, and amoxicillin alone, and in the following combinations: berberine and penicillin, lincomycin, or amoxicillin. After cultivation at 37°C for 18 h under a microaerophilic atmosphere (10% O_2; 5% CO_2), the minimum inhibitory concentrations (MICs) were read as the minimum concentrations of drugs that completely inhibited the visible growth of microorganisms. The final drug concentration ranges were 1024-0.125 μg/mL for penicil-
lin, lincomycin, and amoxicillin and 1024-0.5 μg/mL for berberine. The experiments were repeated a minimum of 3 times.

**Determination of interactions of drug combinations**

The interaction between berberine and penicillin, lincomycin, or amoxicillin was determined by evaluating the fractional inhibitory concentration index (FICI) as previously described (Oo et al., 2010). Briefly, MICs obtained from the checkerboard were further analyzed for FICIs based on the interaction theory of Loewe additivity (LA). The LA theory is based on the idea that a drug cannot interact with itself. FICI was determined from the MICs for each combination and was calculated using the following equation: $FICI = FICA + FICB$, where $FICA = \frac{MIC \text{ of drug A in combination with drug B}}{MIC \text{ of drug A alone}}$, and $FICB = \frac{MIC \text{ of drug B in combination with drug A}}{MIC \text{ of drug B alone}}$. The FICI was interpreted as follows: $FICI \leq 0.5$, synergistic effect; $0.5 < FITC \leq 4.0$, no difference; $FICI > 4.0$, antagonistic effect (Oo et al., 2010). All experiments were repeated 3 times.

**Time-kill assay**

A time-kill assay was conducted using the method described in the CLSI guidelines (CLSI, 2005; Credito et al., 2007). *S. epidermidis* isolate 4 was subjected to a further time-killing assay. Sub-inhibitory concentrations of drugs (alone and in combination) were added to tubes (16 μg/mL penicillin and 128 μg/mL berberine; 64 μg/mL lincomycin and 32 μg/mL berberine; 64 μg/mL amoxicillin and 128 μg/mL berberine). A control tube without antibiotics was included in each series. In all cases, 1 drug in the combination did not affect the microorganism’s growth curves when used alone. Tubes were inoculated with MH broth containing $10^6$ CFU *S. epidermidis* isolate 4 per mL and incubated at 37°C in a shaking incubator. Next, 100 μL culture was removed from each tube at 0, 4, 8, 12, and 24 h after inoculation. Viability counts were conducted on Sabouraud dextrose agar plates after incubation at 35°C for 18 h. A synergistic interaction was defined as a $2 \log_{10}$ decrease of CFU/mL between the drug combination and its most active constituent. An antagonistic interaction was defined as a $2 \log_{10}$ increase in CFU/mL compared with a more active agent of the combination. A change of less than $2 \log_{10}$ CFU/mL was considered to indicate no difference. Each test was repeated at least 3 times.

**Statistical analysis**

Data are reported as means ± standard deviation. The Student t-test was used to compare the means between the 2 groups. One-way analysis of variance was used to compare the means between more than 2 groups, and the comparison between 2 means of multiple groups was based on homogeneity of variance. The SPSS 13.0 software was used for the statistical analysis (SPSS, Inc., Chicago, IL, USA), and $P < 0.05$ indicated a significant difference.

**RESULTS**

**Methicillin-resistant *S. epidermidis* test**

The methicillin resistance of the 18 *S. epidermidis* field isolates was determined fol-
following the NCCLS guidelines for MRSA (NCCLS, 2004). Isolate number 4 of \textit{S. epidermidis} (designated as \textit{S. epidermidis} 4 in this study) was the only isolate resistant to methicillin (cefoxitin inhibition zone diameter = 12 mm), which was chosen for further analysis using the time-kill assay as described below.

**Susceptibility of \textit{S. epidermidis} isolates to antimicrobial agents**

The drug susceptibility of the 18 \textit{S. epidermidis} isolates to berberine, penicillin, lincomycin, and amoxicillin was determined using a microdilution checkerboard assay (Table 1). These field strains isolated from the milk of dairy cows with mastitis were resistant to penicillin (18/18, 100%), lincomycin (18/18, 100%), amoxicillin (12/18, 66.7%), and/or methicillin (1/18, 5.6%). The MICs of berberine against these isolated ranged from 2-512 µg/mL, while the MIC to the control \textit{S. epidermidis} strain was 2 µg/mL (Table 1); the MICs of penicillin, lincomycin, and amoxicillin to \textit{S. epidermidis} clinical isolates ranged from 0.8-213, 10-1024, and 0.4-256 µg/mL, respectively; while the respective MICs of penicillin, lincomycin, and amoxicillin against the reference strain were 0.125, 0.5, and 0.5 µg/mL (Table 1). These results suggest that berberine has antibacterial activity against MDR \textit{S. epidermidis} clinical isolates. In addition, the combinations of berberine with each of the tested antibiotics showed a decreased MIC against the microorganisms tested by 4-16-fold relative to the corresponding agents alone.

### Table 1. Susceptibilities of \textit{Staphylococcus epidermidis} field isolates to commonly used antibiotics.

<table>
<thead>
<tr>
<th>\textit{S. epidermidis} isolates</th>
<th>Alone</th>
<th>In combination with berberine (32 µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Penicillin</td>
<td>Lincomycin</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 1</td>
<td>2.33 ± 1.53</td>
<td>53.33 ± 18.48</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 2</td>
<td>2 ± 0</td>
<td>106.67 ± 36.95</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 3</td>
<td>5.33 ± 2.31</td>
<td>53.33 ± 18.48</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 4</td>
<td>213.33 ± 73.90</td>
<td>1024 ± 0</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 5</td>
<td>4 ± 0</td>
<td>42.67 ± 18.48</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 6</td>
<td>106.67 ± 36.95</td>
<td>18.67 ± 12.22</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 7</td>
<td>10.67 ± 4.62</td>
<td>53.33 ± 18.48</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 8</td>
<td>6.67 ± 2.31</td>
<td>128 ± 0</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 9</td>
<td>10.67 ± 4.62</td>
<td>42.67 ± 18.48</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 10</td>
<td>1.33 ± 0.58</td>
<td>10.67 ± 4.62</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 11</td>
<td>128 ± 0</td>
<td>21.33 ± 9.24</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 12</td>
<td>16 ± 0</td>
<td>64 ± 0</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 13</td>
<td>0.83 ± 0.29</td>
<td>53.33 ± 18.48</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 14</td>
<td>1.33 ± 0.58</td>
<td>16 ± 0</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 15</td>
<td>128 ± 0</td>
<td>256 ± 0</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 16</td>
<td>106.67 ± 36.95</td>
<td>512 ± 0</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 17</td>
<td>128 ± 0</td>
<td>32 ± 0</td>
</tr>
<tr>
<td>\textit{S. epidermidis} 18</td>
<td>64 ± 0</td>
<td>37.33 ± 24.44</td>
</tr>
<tr>
<td>\textit{ATCC12228}</td>
<td>0.125 ± 0</td>
<td>0.5 ± 0</td>
</tr>
</tbody>
</table>

Susceptible or resistant strains were identified according to the interpretive breakpoints of CLSI criteria for penicillin (< 0.25 and ≥ 0.25 µg/mL, respectively); for lincomycin and amoxicillin (< 4 and ≥ 4 µg/mL, respectively) (CLSI, M100-S15, 2005). Results are reported as means ± standard deviation for 3 independent experiments for each condition. *P < 0.05, **P < 0.01 compared to the agent alone.

**Interactive effect of berberine and antibiotics against \textit{S. epidermidis} isolates**

To investigate whether a combination of berberine and antibiotics would yield a syn-
ergistic effect against \textit{S. epidermidis} isolates, the FICI was calculated based on the above MIC data. As shown in Table 2, synergistic effects between berberine and penicillin were observed in most of the isolates tested. Such synergistic interactions were also found when berberine was used in combination with lincomycin or amoxicillin (data not shown). In contrast, such an interaction was not detected in the control strain of \textit{S. epidermidis}. For the control \textit{S. epidermidis} strain, combination treatment exhibited no interaction. Notably, no antagonistic effect was observed with any combinations for any of the strains tested.

\begin{table}[h]
\centering
\caption{In vitro interactions between berberine and penicillin against \textit{Staphylococcus epidermidis} field isolates.}
\begin{tabular}{llllll}
\hline
\textit{S. epidermidis} isolates & FICI penicillin & FICI berberine & FICI combined & Interpretation \\
\hline
\textit{S. epidermidis} 1 & 0.104 (0.063-0.125) & 0.25 (0.25) & 0.354 (0.188-0.625) & SYN \\
\textit{S. epidermidis} 2 & 0.125 (0.125) & 0.25 (0.25) & 0.375 (0.25-0.65) & SYN \\
\textit{S. epidermidis} 3 & 0.125 (0.125) & 0.208 (0.125-0.25) & 0.333 (0.25-0.375) & SYN \\
\textit{S. epidermidis} 4 & 0.104 (0.063-0.125) & 0.25 (0.25) & 0.354 (0.313-0.375) & SYN \\
\textit{S. epidermidis} 5 & 0.25 (0.25) & 0.25 (0.25) & 0.5 (0.375-0.75) & IND \\
\textit{S. epidermidis} 6 & 0.125 (0.125) & 0.104 (0.063-0.125) & 0.229 (0.188-0.25) & SYN \\
\textit{S. epidermidis} 7 & 0.125 (0.125) & 0.125 (0.125) & 0.25 (0.25) & SYN \\
\textit{S. epidermidis} 8 & 0.13 (0.016-0.25) & 0.104 (0.063-0.125) & 0.234 (0.188-0.375) & SYN \\
\textit{S. epidermidis} 9 & 0.208 (0.125-0.25) & 0.25 (0.125-0.5) & 0.458 (0.375-0.625) & SYN \\
\textit{S. epidermidis} 10 & 0.208 (0.125-0.25) & 0.25 (0.25) & 0.458 (0.375-0.5) & SYN \\
\textit{S. epidermidis} 11 & 0.167 (0.125-0.25) & 0.875 (0.125-2) & 1.042 (0.25-2.125) & IND \\
\textit{S. epidermidis} 12 & 0.167 (0.125-0.25) & 0.25 (0.25) & 0.417 (0.375-0.5) & SYN \\
\textit{S. epidermidis} 13 & 0.25 (0.25) & 0.073 (0.31-0.125) & 0.323 (0.281-0.375) & SYN \\
\textit{S. epidermidis} 14 & 0.208 (0.125-0.25) & 0.667 (0.5-1.0) & 0.875 (0.75-1.125) & IND \\
\textit{S. epidermidis} 15 & 0.125 (0.125) & 0.063 (0.063) & 0.188 (0.188) & SYN \\
\textit{S. epidermidis} 16 & 0.104 (0.063-0.125) & 0.104 (0.063-0.125) & 0.208 (0.125-0.25) & SYN \\
\textit{S. epidermidis} 17 & 0.104 (0.063-0.125) & 0.25 (0.25) & 0.354 (0.313-0.375) & SYN \\
\textit{S. epidermidis} 18 & 0.125 (0.125) & 0.292 (0.125-0.5) & 0.417 (0.25-0.625) & SYN \\
\text{ATCC12228} 1 (1) & 0.25 (0.25) & 1.25 (1.25) & 1.25 (1.25) & IND \\
\hline
\end{tabular}
\end{table}

SYN, synergism; IND, indifference. An FICI < 0.5 was defined as a synergistic interaction, 0.5 ≤ FICI < 4 was defined as no interaction (no difference), and an FICI ≤ 4.0 was defined as an antagonistic interaction. Results represent the mean and range for 3 independent experiments for each condition.

**Time-kill analysis**

Isolates of \textit{S. epidermidis} 4 were resistant to penicillin, lincomycin, amoxicillin, and methicillin, and was thus chosen for further synergy studies using a time-killing assay with a combination of berberine with penicillin, lincomycin, or amoxicillin. Synergy time-kill graphs for \textit{S. epidermidis} 4 are shown in Figure 1. The time-kill curves verified the synergistic effect for the combination of berberine and penicillin (Figure 1A), lincomycin (Figure 1B), or amoxicillin (Figure 1C). After 18 h of incubation, synergistic interactions were observed for berberine with the antibiotics, yielding a greater than 2 log\textsubscript{10} CFU/mL decrease in microorganisms, as compared with the most active agent, which was significantly greater than each drug alone (P < 0.01).
Figure 1. Time-kill curves for antimicrobial agents. Berberine and penicillin (A), lincomycin (B), or amoxicillin (C) were tested alone and in combination against Staphylococcus epidermidis 4, a field isolate resistant to penicillin, lincomycin, amoxicillin, and methicillin, using time-kill analysis. Results are reported as means ± standard deviation for 3 independent experiments for each condition.
DISCUSSION

In this study, the in vitro antibacterial activity of berberine against MDR *S. epidermidis* field isolates, either alone or in combination with penicillin, lincomycin, or amoxicillin, was explored. The results demonstrated the potential anti-staphylococcal activity of berberine at MICs of 2-512 μg/mL against MDR *S. epidermidis* isolates. In combination with commonly used antibiotics, the susceptibility of most *Staphylococcus* strains tested compared to these agents alone was dramatically enhanced. This suggests a synergistic interaction between berberine and the antibiotics tested, which was also verified by the results of the time-kill assay. This study suggests that using a combination of existing antibiotics and natural herbal compounds will provide new means of optimal clinical effects, thus increasing efficacy and abating adverse drug reactions. Such a strategy may postpone the development of drug-resistance and enhance the clinical effects of commonly used antimicrobial agents.

CNS are Gram-positive cocci and include flora from the environment (such as *Staphylococcus xylosus*) and teat skin (such as *S. epidermidis*); they are capable of infecting dairy cows and heifers before calving and are important pathogens in cow mastitis with a higher prevalence in primiparous animals. In general, most CNS species are susceptible to commonly used antibiotics for mastitis treatment. However, different antimicrobial susceptibilities and diverse virulence factors were also found in CNS species isolated from mastitis in dairy cows (Taponen and Pyörälä, 2009); this may lead to ineffective treatment when using common antibiotics. In addition, an increasing number of CNS has been reported to be resistant to neomycin, penicillin, tetracycline, streptomycin, lincomycin, and ampicillin (Bochniarz and Wawron, 2011; Onni et al., 2011). Further, MDR isolates of *S. epidermidis* have been identified in the milk from both cows (Sawant et al., 2009; Waller et al., 2011) and women (Delgado et al., 2009), making these isolates a significant threat to public health. Consistent with these findings, most *S. epidermidis* isolates were determined to varying extents of MDR to penicillin, lincomycin, and/or amoxicillin in this study. All 18 (100%) isolates tested were resistant to penicillin and licomycin, and/or 12 of 18 (66.7%) were resistant to amoxicillin, although only 1 isolate (1/18), *S. epidermidis* 4, was methicillin-resistant (5.6%).

An increasing number of studies have demonstrated that numerous herbs have antimicrobial properties, including anti-staphylococcal activity, and herbal medicines were less inclined to induce resistance in the clinical setting. Many lines of evidence have demonstrated the antimicrobial activity of berberine against a variety of bacterial pathogens including MRSA and *S. epidermidis* isolates (Wang et al., 2009a; Yu et al., 2010); berberine showed the potential to inhibit *S. epidermidis* biofilm formation in a previous study (Wang et al., 2009a). Importantly, a combination of berberine and other antimicrobial agents also had a synergistic effect against various pathogens, and such synergisms were observed when used in combination with fluconazole (Xu et al., 2009), miconazole (Wei et al., 2011), itraconazole (Lei et al., 2011), ampicillin, or oxacillin (Yu et al., 2010). The addition of berberine significantly decreased the MICs of these antimicrobial agents against the microorganisms tested compared with these agents alone. For example, a synergistic effect was observed between berberine and oxacillin against MRSA, and berberine showed a synergistic effect by increasing activity of oxacillin while decreasing MIC against MRSA. These results suggest that berberine may restore the effectiveness of beta-lactam antibiotics against MRSA (Yu et al., 2010). Additionally, the anti-staphylococcal activity of berberine was also observed in this study. More importantly, a combination of berberine and antibiotics, including penicillin, lincomycin, and
amoxicillin yielded a synergistic effect against MDR *S. epidermidis* field isolates. These antimicrobial properties of berberine may be useful for controlling and treating mastitis caused by MDR *Staphylococcus* infection in dairy cows.

**CONCLUSIONS**

Our results demonstrate that berberine has antimicrobial properties against MDR *S. epidermidis* strains. Particularly, a favorable synergistic interaction was observed when berberine was used in combination with commonly used antibiotics, including penicillin, lincomycin, and amoxicillin against MDR *Staphylococcus* field isolates. These findings indicate that berberine can be used for the prevention and treatment of *Staphylococcus* causing mastitis in dairy cows, either alone or in combination with other antimicrobial agents.

**ACKNOWLEDGMENTS**

Research supported by grants from the National Natural Science Foundation of China (#31260624 and #31060348), and a grant from the National Science Technology Support Program of China (#2012BAD12B07-4).

**REFERENCES**


X. Zhou et al.


